BioSpace News Archive

– Collaboration to Focus on Oral and Injectable Formulations of Lenacapavir and Islatravir – – Agreement Brings Together Potentially Complementary Medicines in Late-Stage Development with the Goal to Provide Innovative, Long-Acting Treatments in HIV –

Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and personal care, has repurchased approximately $73 million in stock beginning Monday, March 1. Late in 2020, the Amedisys Board of Directors authorized up to $100 million in share repurchases through December 31, 2021.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has completed enrollment in its Phase 2a clinical trial of ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, for the potential treatment of moderate to severe atopic dermatitis

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Sophia Randolph, M.D., Ph.D., to its Board of Directors.

Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK), (NASDAQ: CHEKZ), today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application,

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser , president and chief executive officer, will present at the Oppenheimer 31 st Annual Healthcare Conference

Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang , will present at

Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announce that the Dronabinol Soft Gel capsules New Drug Submission file submitted to Health Canada on December 30, 2020 has completed the screening phase.

PureTech Health plc plans to publish its annual report and financial results on Thursday, April 15, 2021 at 2:00 AM EDT / 7:00 AM BST.

Dearth of highly effective treatment approaches combined with the emergence of more intricate forms of lung cancers is prompting companies to initiate research projects and trials to test the efficacy of gemcitabine HCL in this domain